Combined Analyses of Circulating Tumor DNA and Immunoscore in Patients With Stage III Colon Cancer: A Post Hoc Analysis of the PRODIGE-GERCOR IDEA-France/HORG-IDEA-Greece Trials

In this combined analysis of two adjuvant trials dedicated to patients with stage III CC after surgery, ctDNA was detectable in 19.7% of the patients and was confirmed as a major independent prognostic biomarker. IS seems to bring additional prognostic information in the 80.3% of patients who are ctDNA-negative.

Authors

Institutions

Publication Details

Journal
Journal of Clinical Oncology
Published
2025-02-04
DOI
https://doi.org/10.1200/jco.24.00648
Citations
15
Primary Topic
Cancer Genomics and Diagnostics
Type
article
Field-Weighted Citation Impact
14.04

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Combined Analyses of Circulating Tumor DNA and Immunoscore in Patients With Stage III Colon Cancer: A Post Hoc Analysis of the PRODIGE-GERCOR IDEA-France/HORG-IDEA-Greece Trials

Christophe Louvet, Ioannis Boukovinas, Konstantinos Vogiatzoglou, Julien Taı̈eb et al.
15 citations
Journal of Clinical Oncology
Cancer Genomics and Diagnostics
14.04
article

Combined Analyses of Circulating Tumor DNA and Immunoscore in Patients With Stage III Colon Cancer: A Post Hoc Analysis of the PRODIGE-GERCOR IDEA-France/HORG-IDEA-Greece Trials

Christophe Louvet, Ioannis Boukovinas, Konstantinos Vogiatzoglou, Julien Taı̈eb, Minetta C. Liu, Jaafar Bennouna, Thibault Mazard, Pascal Artru, Himanshu Sethi, Céline Lepère, Jean‐François Emile, Jérôme Galon, Olivier Bouché, John Souglakos, Thierry André, Ippokratis Messaritakis, Franck Pagès, Maria Tzardi, Pierre Laurent‐Puig, Shruti Sharma, Déwi Vernerey, Antoine Falcoz
article en
15 citations

Abstract

In this combined analysis of two adjuvant trials dedicated to patients with stage III CC after surgery, ctDNA was detectable in 19.7% of the patients and was confirmed as a major independent prognostic biomarker. IS seems to bring additional prognostic information in the 80.3% of patients who are ctDNA-negative.

Journal of Clinical OncologyVol. 43(13)
Centre National de la Recherche Scientifique (FR), University of Crete (GR), Inserm (FR), Université de Montpellier (FR), Université Paris Cité (FR), Sorbonne Université (FR), Sorbonne Paris Cité (FR), Institute Mutualiste Montsouris (FR), Centre de Recherche des Cordeliers (FR), Methodology and Quality of Life Unit in Oncology (FR), La Ligue Contre le Cancer (FR), Assistance Publique – Hôpitaux de Paris (FR), Hôpital Européen Georges-Pompidou (FR), Hôpital Saint-Antoine (FR), Natera (United States) (US), Hôpital Robert-Debré (FR), Hôpital Privé Jean Mermo (FR), Établissement Français du Sang (FR), Laboratoire d’immunologie intégrative du cancer (FR), University Hospital of Heraklion (GR), Institut de Recherche en Cancérologie de Montpellier (FR), Hôpital Foch (FR)
Sanofi, Veracyte, Natera, Fondation ARC pour la Recherche sur le Cancer, Institut National Du Cancer
Good health and well-being
Openalex Percentile: Top 1%
Cancer Genomics and Diagnostics
14.04
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.